ArticlemBio2025
PEDV NSP8 inhibits IFN-III production induced by MAVS through downregulation of PEX13.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.Journal of virology · 2026Article
- Genome-wide CRISPR screen reveals PEX11B as a host restriction factor against ORFV through membrane fluidity regulation.PLoS pathogens · 2026Article
- PEX19 restricts porcine deltacoronavirus replication through farnesylation-dependent and -independent mechanisms.Journal of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine epidemic diarrhea virus (PEDV), an enteropathogenic coronavirus that causes severe intestinal disease in piglets, employs sophisticated strategies to subvert host antiviral immunity. While type III interferons (IFN-III) play a pivotal role in mucosal defense at intestinal epithelial barriers, the mechanisms underlying PEDV evasion of IFN-III signaling remain poorly understood. Given that peroxisomes serve as critical platforms for IFN-III signaling and that their abundance influences immune activation, we investigated the role of pexophagy in PEDV-mediated immune evasion. We demonstrated that the PEDV nonstructural protein NSP8 functions as a potent inhibitor of mitochondrial antiviral-signaling protein (MAVS)-dependent IFN-III production. Functional analyses revealed that NSP8 significantly reduces peroxisomal protein levels and promotes pexophagy. Mechanistically, mass spectrometry identified a direct interaction between NSP8 and PEX13. NSP8 also induces dose-dependent degradation of PEX13 via the autophagy-lysosomal pathway. This downregulation of PEX13 triggers ubiquitination of the peroxisomal import receptor PEX5, facilitating its recognition by the autophagy receptor NBR1 and the ubiquitin ligase PEX2, thereby promoting autophagic clearance of peroxisomes. Collectively, our findings reveal a novel immune evasion strategy in which PEDV exploits NSP8 to disrupt peroxisome homeostasis by targeting PEX13, thereby dismantling MAVS-dependent IFN-III antiviral signaling through pexophagy. IMPORTANCE: Porcine epidemic diarrhea virus (PEDV) NSP8 is a highly conserved protein that plays a crucial role in viral replication. Investigating the functional mechanisms of NSP8 contributes to a deeper understanding of PEDV pathogenesis and supports the development of antiviral strategies against coronaviruses. In this study, we elucidate how NSP8 suppresses type Ⅲ interferon (IFN-Ⅲ) production by promoting pexophagy through the downregulation of PEX13. We demonstrate that NSP8 directly interacts with PEX13 and enhances the ubiquitination of PEX5, leading to reduced peroxisome abundance and impaired mitochondrial antiviral-signaling protein (MAVS)-mediated IFN-Ⅲ signaling. These findings suggest that NSP8 hijacks the PEX13-dependent pexophagy pathway as a means of evading host antiviral defenses. This work provides critical insights into the interplay between viral proteins and host cellular machinery and highlights the NSP8-PEX13 axis as a promising target for therapeutic interventions aimed at enhancing antiviral immunity against PEDV and related coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.